Leo Acquisitions Enters into Binding Letter of Intent for Qualifying Transaction with PsyBio Therapeutics
Not for distribution to United States newswire services or for dissemination in the United States.
TORONTO, Oct. 05, 2020 (GLOBE NEWSWIRE) — Leo Acquisitions Corp. (TSXV: LEQ.H) (“Leo” or the “Company”) and PsyBio Therapeutics, Inc. (“PsyBio”) are pleased to announce that they have entered into a binding letter of intent dated October 5, 2020, pursuant to which Leo and PsyBio intend to complete a business combination or other similarly structured transaction which will constitute a reverse take-over of Leo (the “Transaction”). It is intended that the Transaction will be an arm’s length “Qualifying Transaction” for Leo, as such term is defined in Policy 2.4 of the Corporate Finance Manual of the TSX Venture Exchange (the “TSXV”).About PsyBio TherapeuticsPsyBio is a US-based biotechnology company developing a new class of drugs intended for the treatment of mental health challenges and other disorders. In collaboration with Miami University based in Oxford, Ohio, PsyBio has retained the global exclusive rights to a proprietary platform technology that biologically synthesizes psilocybin and other targeted next generation psychoactive compounds that are produced naturally in fungi and plants (the “PsyBio IP”). Management of PsyBio expects that the PsyBio IP will enable the rapid generation of these highly stable psychoactive compounds cheaper, faster and greener than other published methods.About Leo AcquisitionsLeo was incorporated under the Business Corporations Act (Ontario) on October 28, 2009 and is a Capital Pool Company (as defined in the policies of the TSXV) listed on the NEX board of the TSXV. Leo has no commercial operations and no assets other than cash.The TransactionThere are no relationships between any non-arm’s length party of Leo and PsyBio or its assets and the Transaction will be an arm’s length transaction. A comprehensive news release will be issued by Leo and PsyBio setting out the terms of the Transaction, which shall include information about Leo upon closing of the Transaction and the proposed financing of PsyBio in connection with the Transaction (the “Concurrent Financing”).Cautionary Note Regarding Forward Looking InformationThis press release contains statements that constitute “forward-looking information” (“forward-looking information”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking information and are based on expectations, estimates and projections as at the date of this news release. Any statement that discusses predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking information. In disclosing the forward-looking information contained in this press release, the Company has made certain assumptions, including that: the Concurrent Financing will be completed on acceptable terms or at all; all applicable shareholder, and regulatory approvals for the Transaction will be received; and the safety and efficacy of the PsyBio IP and that it will be cheaper, faster and greener than other published methods. Although the Company believes that the expectations reflected in such forward-looking information are reasonable, it can give no assurance that the expectations of any forward-looking information will prove to be correct. Known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking information. Such factors include, but are not limited to: availability of financing; delay or failure to receive board, shareholder or regulatory approvals; and general business, economic, competitive, political and social uncertainties. Accordingly, readers should not place undue reliance on the forward-looking information contained in this press release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking information to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward-looking information or otherwise.For further information contact:Gerry Goldberg
CEO, Leo Acquisitions Corp.
e: gerrygoldbergcpa@gmail.comEvan Levine
CEO, PsyBio Therapeutics, Inc.
p: 650-305-0553
e: evan@psybiolife.comThis news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.All information provided in this press release relating to PsyBio has been provided by management of PsyBio and has not been independently verified by management of the Company. As the date of this press release, the Company has not entered into a definitive agreement with PsyBio with respect to the Transaction (the “Definitive Agreement”), and readers are cautioned that there can be no assurances that a Definitive Agreement will be executed.Completion of the Transaction is subject to a number of conditions, including but not limited to, TSXV acceptance and, if applicable pursuant to TSXV requirements, majority of the minority shareholder approval. Where applicable, the Transaction cannot close until the required shareholder approval is obtained. There can be no assurance that the Transaction will be completed as proposed or at all.Investors are cautioned that, except as disclosed in the management information circular or filing statement to be prepared in connection with the Transaction, any information released or received with respect to the Transaction may not be accurate or complete and should not be relied upon. Trading in the securities of a capital pool company should be considered highly speculative.The TSXV has in no way passed upon the merits of the proposed Transaction and has neither approved nor disapproved the contents of this press release. Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.
TORONTO, Oct. 05, 2020 (GLOBE NEWSWIRE) — Leo Acquisitions Corp. (TSXV: LEQ.H) (“Leo” or the “Company”) and PsyBio Therapeutics, Inc. (“PsyBio”) are pleased to announce that they have entered into a binding letter of intent dated October 5, 2020, pursuant to which Leo and PsyBio intend to complete a business combination or other similarly structured transaction which will constitute a reverse take-over of Leo (the “Transaction”). It is intended that the Transaction will be an arm’s length “Qualifying Transaction” for Leo, as such term is defined in Policy 2.4 of the Corporate Finance Manual of the TSX Venture Exchange (the “TSXV”).About PsyBio TherapeuticsPsyBio is a US-based biotechnology company developing a new class of drugs intended for the treatment of mental health challenges and other disorders. In collaboration with Miami University based in Oxford, Ohio, PsyBio has retained the global exclusive rights to a proprietary platform technology that biologically synthesizes psilocybin and other targeted next generation psychoactive compounds that are produced naturally in fungi and plants (the “PsyBio IP”). Management of PsyBio expects that the PsyBio IP will enable the rapid generation of these highly stable psychoactive compounds cheaper, faster and greener than other published methods.About Leo AcquisitionsLeo was incorporated under the Business Corporations Act (Ontario) on October 28, 2009 and is a Capital Pool Company (as defined in the policies of the TSXV) listed on the NEX board of the TSXV. Leo has no commercial operations and no assets other than cash.The TransactionThere are no relationships between any non-arm’s length party of Leo and PsyBio or its assets and the Transaction will be an arm’s length transaction. A comprehensive news release will be issued by Leo and PsyBio setting out the terms of the Transaction, which shall include information about Leo upon closing of the Transaction and the proposed financing of PsyBio in connection with the Transaction (the “Concurrent Financing”).Cautionary Note Regarding Forward Looking InformationThis press release contains statements that constitute “forward-looking information” (“forward-looking information”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking information and are based on expectations, estimates and projections as at the date of this news release. Any statement that discusses predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking information. In disclosing the forward-looking information contained in this press release, the Company has made certain assumptions, including that: the Concurrent Financing will be completed on acceptable terms or at all; all applicable shareholder, and regulatory approvals for the Transaction will be received; and the safety and efficacy of the PsyBio IP and that it will be cheaper, faster and greener than other published methods. Although the Company believes that the expectations reflected in such forward-looking information are reasonable, it can give no assurance that the expectations of any forward-looking information will prove to be correct. Known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking information. Such factors include, but are not limited to: availability of financing; delay or failure to receive board, shareholder or regulatory approvals; and general business, economic, competitive, political and social uncertainties. Accordingly, readers should not place undue reliance on the forward-looking information contained in this press release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking information to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward-looking information or otherwise.For further information contact:Gerry Goldberg
CEO, Leo Acquisitions Corp.
e: gerrygoldbergcpa@gmail.comEvan Levine
CEO, PsyBio Therapeutics, Inc.
p: 650-305-0553
e: evan@psybiolife.comThis news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.All information provided in this press release relating to PsyBio has been provided by management of PsyBio and has not been independently verified by management of the Company. As the date of this press release, the Company has not entered into a definitive agreement with PsyBio with respect to the Transaction (the “Definitive Agreement”), and readers are cautioned that there can be no assurances that a Definitive Agreement will be executed.Completion of the Transaction is subject to a number of conditions, including but not limited to, TSXV acceptance and, if applicable pursuant to TSXV requirements, majority of the minority shareholder approval. Where applicable, the Transaction cannot close until the required shareholder approval is obtained. There can be no assurance that the Transaction will be completed as proposed or at all.Investors are cautioned that, except as disclosed in the management information circular or filing statement to be prepared in connection with the Transaction, any information released or received with respect to the Transaction may not be accurate or complete and should not be relied upon. Trading in the securities of a capital pool company should be considered highly speculative.The TSXV has in no way passed upon the merits of the proposed Transaction and has neither approved nor disapproved the contents of this press release. Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.
